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Background: Adult weight gain and obesity have become worldwide problems. Issues of 
cost and potential side effects of prescription weight loss drugs have led overweight and obese 
adults to try nutraceuticals that may aid weight loss. One promising nutraceutical is green cof-
fee extract, which contains high concentrations of chlorogenic acids that are known to have 
health benefits and to influence glucose and fat metabolism. A 22-week crossover study was 
conducted to examine the efficacy and safety of a commercial green coffee extract product 
GCA™ at reducing weight and body mass in 16 overweight adults.
Methods: Subjects received high-dose GCA (1050 mg), low-dose GCA (700 mg), or placebo 
in separate six-week treatment periods followed by two-week washout periods to reduce any 
influence of preceding treatment. Treatments were counterbalanced between subjects. Primary 
measurements were body weight, body mass index, and percent body fat. Heart rate and blood 
pressure were also measured.
Results: Significant reductions were observed in body weight (−8.04 ± 2.31 kg), body mass index 
(−2.92 ± 0.85 kg/m2), and percent body fat (−4.44% ± 2.00%), as well as a small decrease in 
heart rate (−2.56 ± 2.85 beats per minute), but with no significant changes to diet over the course 
of the study. Importantly, the decreases occurred when subjects were taking GCA. Body mass 
index for six subjects shifted from preobesity to the normal weight range (,25.00 kg/m2).
Conclusion: The results are consistent with human and animal studies and a meta-analysis 
of the efficacy of green coffee extract in weight loss. The results suggest that GCA may be an 
effective nutraceutical in reducing weight in preobese adults, and may be an inexpensive means 
of preventing obesity in overweight adults.
Keywords: green coffee bean extract, chlorogenic acid, body mass index, weight loss, body 
fat mass, blood pressure, heart rate
Introduction
The World Health Organization predicts there will be 2.3 billion overweight adults 
in the world by 2015, and more than 700 million of them will be obese. Worldwide 
obesity has more than doubled since 1980. In 2008, 1.5 billion adults, 20 years of age 
and older, were overweight. Of these, over 200 million men and nearly 300   million 
women were obese. Over 65% of the world population lives in countries where 
overweight and obesity kills more people than underweight.1 With the high cost of 
prescription weight loss drugs and the fear of side effects, the general public is turning 
to nutraceuticals. The estimated global market for 2014 is over 350 billion US dollars, 
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At the present time, there is only one nonprescription 
nutraceutical product that is currently under investigation 
(Pharmachem Laboratory, Phase II) and is approved by the 
US Food and Drug Administration, with a qualified health 
claim for assistance in weight control and a structure-function 
claim for its mechanism, which is that it blocks starch absorp-
tion by means of an α-amylase inhibitor.3,4 Coffee is of inter-
est as a possible nutraceutical for weight loss because caffeine 
is a well known stimulant, and an epidemiology study found 
that coffee consumption resulted in less weight gain in obese 
men over an 18-month period.5 A polysaccharide ingredient 
in coffee caused weight reduction when added to the diet of 
obese men but was not effective for women.6 Freeze-dried 
coffee was found to cause weight loss when given to rats. 
It also increased antioxidant enzymes.7 Caffeine, the major 
stimulant in coffee, has been linked to weight loss and to 
reduction in the risk of metabolic syndrome.8 Existing but 
limited evidence suggests that substituting coffee for energy-
containing soft drinks may facilitate weight management.9 
Several epidemiological investigations have found that 
coffee consumption reduces the risk of type 2 diabetes, and 
one of the mechanisms proposed for this benefit is that   coffee 
consumption is inversely associated with weight gain.10 The 
purpose of this study was to investigate the efficacy of a 
high chlorogenic acid green coffee bean extract in reducing 
weight, body mass, and body fat percentage, in preobese, 
euthyroid (normal thyroid functioning), otherwise healthy 
human subjects.
Materials and methods
Subjects
The study included 16 subjects (eight males and eight females) 
aged 22–46 (mean 33.19 ± 6.75) years.   Average body mass 
index (BMI) at the start of the study was 28.22 ± 0.91 kg/m2. 
The mean values for additional measures taken at baseline 
are listed in Table 1. Subjects exhibited overweight (pre-
obesity) levels, as indexed by BMI 25–30, with the average 
duration of prevalent BMI being 10.9 ± 3.9 months prior 
to the onset of the study. Duration of prevalent BMI was 
determined by examining health records of each subject 
prior to the beginning of the study. All subjects were euthy-
roid, nondiabetic (mean blood glucose 107 ± 9 mg/dL), and 
nonhypertensive (mean systolic/diastolic blood pressure 
125.38/81.88 ± 5.10/2.68 mmHg), and were not on or been 
receiving steroids in the recent past. No subject was on or had 
been recently on medications known to influence weight for 
the past 6 months. All subjects had similar diet and exercise 
profiles and diet was recorded before and at the end of the 
study (see Table 3 for average diet information). All subjects 
gave their written informed consent before beginning the 
study. Informed consent was of a standard format, as per 
Indian regulatory requirements governing research human 
subject research, which are consistent with the ethical prin-
ciples put forth in the Declaration of Helsinki.
Materials
The green coffee extract utilized for this study was   provided 
by Applied Food Sciences Inc (Austin, TX) under the 
trade name GCA®. GCA contains a standard green   coffee 
extract of total chlorogenic acids assayed at 45.9%, with 
other hydroxycinnamic acids that are known to have anti-
oxidant health benefits. The total chlorogenic acid and 
other hydroxycinnamic acid content was 56.66%. Caffeine 
content was 2%–4% and assayed at 2.60% ± 0.18% for 
two lots. The relevant polyphenols and caffeine assay 
was done by ChromaDex Analytical (Irvine, CA) using 
high-performance liquid chromatography and appropriate 
standards. This study utilized two dosage levels of GCA, 
as well as a placebo. The high-dose condition was 350 mg 
of GCA taken orally three times daily. The low-dose con-
dition was 350 mg of GCA taken orally twice daily. The 
placebo condition consisted of a 350 mg inert capsule of 
an inactive substance taken orally three times daily. The 
two dosages of GCA used here were based on previous 
Table 1 characteristics of 16 preobese subjects at baseline and end of study
Characteristic Baseline (week 0) 
M ± SD
End of study (week 22) 
M ± SD
Difference (week 22 - week 0) 
M ± SD
Change
Weight (kg)   76.69 ± 7.91   68.65 ± 7.78 −8.04 ± 2.31** −10.5%
BMi (kg/m2)   28.22 ± 0.91   25.25 ± 1.19 −2.92 ± 0.85** −10.3%
Percent body fat   28.13 ± 4.95   23.69 ± 4.95 −4.44 ± 2.00** −15.8%
hr (bpm)   77.44 ± 4.15   74.88 ± 3.42 −2.56 ± 2.85*  − 3.3%
SBP (mmhg) 125.38 ± 5.10 130.25 ± 9.60   4.88 ± 11.24   3.9%
DBP (mmhg)   81.88 ± 2.68   83.38 ± 3.70   1.50 ± 4.41   1.8%
Notes: *P , 0.005; **P , 0.0001.
Abbreviations: BMi, body mass index; hr, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; M, median; SD, standard deviation.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012:5 submit your manuscript | www.dovepress.com
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experience using chlorogenic acids in a human study of 
the decrease in postprandial glucose.
Study design
This was a randomized, double-blind, 22-week study that 
implemented a crossover design to compare a low-dose 
green coffee extract, a high-dose green coffee extract, and 
a placebo. Subjects were randomly assigned to a high-dose/
low-dose/placebo sequence (n = 6), low-dose/placebo/
high-dose sequence (n = 4), or placebo/high-dose/low-dose 
sequence (n = 6). Subjects stayed on a treatment for a period 
of 6 weeks, followed by a 2-week washout period, before the 
next treatment period began.
Subjects were examined at weeks 0, 6, 8, 14, 16, and 22 
of the study. Subjects were examined individually at Trinity 
Hospital, Bangalore, India. During each visit, the following 
measurements were taken: body weight to nearest 0.01 kg, 
height to nearest 0.01 cm, and a body fat percentage analysis 
using a SFB7 Bioimpedance device. BMI was determined 
using the formula of BMI = weight in kg divided by the 
square of the height in meters. All subjects were counseled 
for diet and exercise compliance at every visit, with the initial 
interview to establish diet details at the start of the study done 
by the site nutritionist. Data gathered included daily calorie 
intake, nutrient composition, micronutrient intake, and inci-
dence of binge eating (see Table 3 for average diet intake 
information). The same procedure was repeated at the begin-
ning of each cycle to reflect the diet during the previous cycle 
and subjects underwent pre- and post-assessment systolic and 
diastolic blood pressure and heart rate measurements, at every 
visit. Blood pressure was measured in the right forearm of 
the subject in a sitting position after a 10-minute rest using 
a standard mercury sphygmomanometer.
Statistical analysis
The primary measures in this study were weight, BMI, and 
body fat percentage; however, heart rate and blood pressure 
taken at each visit were also analyzed. Statistical analyses 
were carried out with a repeated-measures analysis of vari-
ance and post hoc t-tests. Factors for the analysis of vari-
ance were sequence (high-dose/low-dose/placebo versus 
low-dose/placebo/high-dose versus placebo/high-dose/
low-dose), treatment arm (first versus second versus third 
treatment), and time (two evaluations per treatment arm). 
For the time factor, the first evaluation within each treat-
ment arm (weeks 0, 8, 16) was considered a pretreatment 
evaluation, and the second evaluation within each treatment 
arm (weeks 6, 14, 22) was a post-treatment evaluation. 
A statistically significant time × arm interaction indicates 
drug effects, ie, individually for the high-dose, low-dose, 
or placebo   conditions. A   significant sequence × arm × time 
interaction would indicate significant differences between 
the drug effects. Finding these interactions significant in the 
omnibus analysis of variance would validate the comparisons 
made between the beginning and end data.
Results
The statistical analyses report the test statistic P value. 
From the mean data reported in Table 1 there were statisti-
cally significant reductions in weight, BMI, percent body 
fat, and heart rate after consuming GCA for two-thirds of 
the 22-week crossover study, but there was no overall sig-
nificant change in systolic or diastolic blood pressure. The 
mean values on all measures at the beginning and end of 
each treatment arm (high-dose, low-dose, placebo) assessed 
for all 16 subjects, are displayed in Table 2. The data show 
a reduction in weight, BMI, and percent body fat in the 
high-dose and low-dose arms, but not the placebo arm, and 
a reduction in heart rate in the high-dose arm, but not the 
low-dose and placebo arms. Figure 1 shows the mean weight 
change across the 22-week study for each of the three groups, 
and Figure 2 shows the mean change in BMI. A three-way 
repeated-measures analysis of variance (factor 1: sequence 
[high-dose/low-dose/placebo versus low-dose/placebo/high-
dose versus placebo/high-dose/low-dose]; arm [first versus 
second versus third treatment]; and time [two evaluations]) 
on the data from all 16 subjects who were randomized into 
the crossover design was conducted on each of the primary 
outcome measures (weight, BMI, and percent body fat), as 
well as diastolic blood pressure, systolic blood pressure, 
and heart rate.
Primary outcome measures
There was a significant treatment arm effect for weight 
(P , 0.001), BMI (P , 0.001), and percent body fat 
(P , 0.001), showing an improvement in each measure over 
the course of the study. There was a significant time effect for 
weight (P , 0.001), BMI (P , 0.001), and percent body fat 
(P , 0.001), showing an improvement between the beginning 
and end for each arm. There was no significant difference 
between the three sequences (P . 0.373).
The sequence × arm interaction was significant for 
weight (P , 0.004), BMI (P , 0.004), and percent body 
fat (P , 0.002), indicating an overall difference in the arms 
across the three sequences, ie, a differential influence of 
each arm on each sequence. The arm × time interaction was Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012:5 submit your manuscript | www.dovepress.com
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significant for weight (P , 0.001), BMI (P , 0.001), and 
percent body fat (P , 0.03), indicating overall drug effects. 
This can be seen in Table 2, where there were improvements 
in weight, BMI, and percent body fat in the high-dose and 
low-dose arms, but not the placebo arm. For weight, the 
2.04 ± 2.20 kg decrease in the high-dose arm was significant 
(P , 0.003), as was the 1.54 ± 1.74 kg decrease in the low-
dose arm (P , 0.005); but the −0.34 ± 1.41 kg change in the 
placebo arm was not significant (P = 0.355). For BMI, the 
0.74 ± 0.80 kg/m2 decrease in the high-dose arm was signifi-
cant (P , 0.003), as was the 0.58 ± 0.66 kg/m2 decrease in 
the low-dose arm (P , 0.004); but the −0.12 ± 0.51 kg/m2 
change in the placebo arm was not significant (P = 0.384). 
For percent body fat, the 1.19% ± 1.22% decrease in the 
high-dose arm was significant (P , 0.002), as was the 
1.06% ± 1.12% decrease in the low-dose arm (P , 0.003); 
surprisingly, the decrease was also significant in the placebo 
arm 0.88% ± 1.26% (P = 0.015). The sequence × time inter-
action was marginally nonsignificant for weight, (P = 0.08), 
was marginally significant for BMI (P = 0.049), and was 
significant for percent body fat (P , 0.001).
Most importantly, the triple interaction was significant for 
weight (P , 0.001) and BMI (P , 0.001), but not for percent 
body fat (P = 0.239). For weight, the 2.04 ± 2.20 kg decrease in the 
high-dose arm was greater than the 0.34 ± 1.41 kg increase in the 
placebo arm (P , 0.013), and the 1.54 ± 1.74 kg decrease in 
the low-dose arm was greater than the 0.34 ± 1.41 kg increase in 
the placebo arm (P , 0.001). The change in weight in the high-
dose arm was not different from the change in weight in the low-
dose arm (P = 0.544). For BMI, the 0.74 ± 0.80 kg/m2 decrease 
in the high-dose arm was greater than the −0.12 ± 0.51 kg/m2 
change in the placebo arm (P , 0.013), and the 0.58 ± 0.66 kg/m2 
decrease in the low-dose arm was greater than the change in the 
placebo arm (P , 0.002). The change in BMI for the high-dose 
arm and low-dose arm did not differ (P = 0.589). A telephone 
interview was done 4 months post-trial, and 14 of the 16 subjects 
maintained their weight loss at the end of the study, while two 
subjects gained 1 kg and 0.75 kg.
Vital measures
Similar repeated-measures analysis of variance were 
performed on vital measures (heart rate, systolic blood 
Table 2 characteristics at start and end of each treatment arm for 16 preobese subjects
Characteristic HD arm P LD arm P PL arm P
Start 
M ± SD  
(95% CI)
End 
M ± SD  
(95% CI)
Start 
M ± SD  
(95% CI)
End 
M ± SD  
(95% CI)
Start 
M ± SD  
(95% CI)
End 
M ± SD  
(95% CI)
Weight (kg) 72.86 ± 8.91  
(68.11–77.61)
70.82 ± 8.40  
(66.34–75.30)
0.002 71.25 ± 7.30  
(67.36–75.14)
69.71 ± 7.30  
(65.82–73.60)
0.003 72.15 ± 8.64  
(67.55–76.75)
72.47 ± 8.47  
(67.96–76.98)
0.353
BMi (kg/m2) 26.78 ± 1.55  
(25.95–27.61)
26.03 ± 1.36  
(25.31–26.75)
0.002 26.25 ± 1.37  
(25.52–26.98)
25.66 ± 1.20  
(25.02–26.30)
0.003 26.55 ± 1.96  
(25.51–27.59)
26.67 ± 1.72  
(25.75–27.59)
0.384
Percent body fat 25.94 ± 5.35  
(23.09–28.79)
24.75 ± 5.20  
(21.98–27.52)
0.001 25.94 ± 4.99  
(23.28–28.60)
24.88 ± 4.99  
(22.22–27.54)
0.002 25.88 ± 5.40  
(23.00–28.76)
25.00 ± 5.52  
(22.20–27.82)
0.014
hr (bpm) 76.94 ± 2.64  
(75.53–78.35)
75.12 ± 3.63  
(73.19–77.05)
0.031 74.62 ± 4.56  
(72.19–77.05)
74.87 ± 4.50  
(72.47–77.27)
0.752 76.19 ± 5.13  
(73.46–78.92)
75.81 ± 4.10  
(73.63–77.99)
0.549
SBP (mmhg) 129.12 ± 8.10  
(124.80–133.44)
129.62 ± 6.74 
(126.03–133.21)
0.843 131.00 ± 6.93 
(127.31–134.69)
128.25 ± 6.40  
(124.84–131.66)
0.221 125.62 ± 6.90  
(121.94–129.30)
131.62 ± 9.33 
(126.65–136.59)
0.031
DBP (mmhg) 81.75 ± 3.00  
(80.15–83.35)
81.62 ± 3.28  
(79.87–83.37)
0.926 81.62 ± 9.24  
(76.70–86.54)
83.00 ± 3.58  
(81.09–84.91)
0.239 82.62 ± 2.39  
(82.35–84.89)
83.50 ± 4.23  
(81.25–85.75)
0.379
Abbreviations: CI, confidence interval; HD, high dose green coffee extract; LD, low dose green coffee extract; PL, placebo; BMI, body mass index; HR, heart rate; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; M, mean; SD, standard deviation.
Table 3 Diet profile for 16 preobese subjects at beginning and during each arm of the study
Measurement  
time
Daily calorie  
intake (%) 
M ± SD
Daily carbohydrate  
intake (%) 
M ± SD
Daily fat  
intake (%) 
M ± SD
Daily protein  
intake (%) 
M ± SD
Binge eating   
incidence 
(n)
Beginning of study 2443.75 ± 260.69 58.75 ± 8.06 25.00 ± 9.66 16.25 ± 6.19 0
Arm 1 2406.25 ± 161.12 60.00 ± 6.32 24.38 ± 8.14 15.62 ± 6.29 0
Arm 2 2393.75 ± 161.12 61.25 ± 7.19 23.12 ± 10.14 15.62 ± 6.29 0
Arm 3 (end of study) 2418.75 ± 137.69 59.38 ± 6.80 25.00 ± 8.94 15.62 ± 6.29 0
Abbreviations: M, mean; SD, standard deviation.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012:5 submit your manuscript | www.dovepress.com
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pressure, diastolic blood pressure). For heart rate, there was 
a marginally nonsignificant sequence effect (P = 0.065), and 
arm × time interaction (P = 0.083). The only significant result 
was a time effect (P , 0.007), reflecting an improvement 
between the beginning and end for each arm. No other effect 
was significant (P . 0.165). There were no significant results 
in the analysis of diastolic blood pressure (P . 0.202). For 
systolic blood pressure, there was a significant arm effect 
(P , 0.005), reflecting a surprising increase in systolic 
blood pressure across the three arms. There was also a 
marginally nonsignificant triple interaction (P = 0.055) 
versus 14 weeks.
All subjects completed the study and there were no 
side effects of using GCA. Regarding nutrient intake, there 
were no significant changes in calories, percentage carbo-
hydrates, percentage fat, or percentage proteins at any time 
during the study. In looking at the individual effects of the 
GCA; 16 of 16 lost weight, 16/16 had decreased percent 
body fat 16/16 had a reduction in BMI, 3/13 experienced 
a decrease in systolic blood pressure, and 5/16 a reduction 
in diastolic blood pressure. Twelve of 16 had a decrease in 
heart rate. The decrease in heart rate of 2 beats per minute 
was significant but was of a lower magnitude than produced 
by a thermogenic combination of polyphenols, hesperidin, 
naringenin, and p-synephrine.11 The lowest heart rate at the 
end of the study was 68 beats per minute. According to one 
of the cited study authors a decrease of 2 beats per minute is 
not clinically significant (H Preuss, personal communication) 
but is of benefit for heart health.
Discussion
The mechanism(s) of the significant effects of GCA on weight 
loss, BMI, percent body fat, and heart rate are unknown. There 
have been some recent articles indicating that chlorogenic acid 
and its metabolite, caffeic acid, inhibit amylase at mM concen-
trations in vitro which, if it occurred in the gastrointestinal tract 
in vivo, would inhibit sugar absorption from starch consump-
tion and thus decrease caloric input.12 That chlorogenic acid 
has a significant influence on glucose metabolism was well 
demonstrated by Rodrigues de Sotillo et al when they were able 
to demonstrate a significant improvement in glucose tolerance 
in Zucker rats.13 This relative deprivation of glucose could 
possibly explain the reduction in BMI as well as fat content 
seen in their other rat study14 and in our human study. Another 
group has clearly demonstrated that chlorogenic acid may in 
fact have an antagonistic effect on human glucose transport.15 
Based on the dietary data in our study, the product was not an 
appetite suppressant. Extracts of green coffee beans inhibited 
pancreatic lipase in vitro with a 50% inhibitory concentration 
of 43 µM polyphenols.16 In support of this result, caffeinated 
but not decaffeinated coffee supplementation in humans pro-
duced a decrease in lipoprotein lipase.17
Animal experiments have additionally demonstrated 
the effect of green coffee extract on fat metabolism, with 
chlorogenic acid alone having a moderate effect.18 They 
were able to obtain significant data suggesting that chlo-
rogenic acid not only retards the absorption of fats from 
the intestine but also activates fat metabolism in the liver. 
This was demonstrated by significantly lower levels of liver 
triglycerides after chlorogenic acid ingestion. A recent study 
in Japan found that coffee polyphenols enhance energy 
metabolism and reduce lipogenesis by downregulating sterol 
regulatory element-binding protein and similar molecules, 
which leads to the suppression of body fat accumulation.19 
Recently, intraperitoneal injection of chlorogenic acid to 
hamsters fed a high-fat diet caused an improvement in lipid 
profile, reduction in hepatic lipase, reduction in glucose and 
insulin and increased expression of peroxisome proliferator-
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activated receptor. This is one of the key regulators of lipids 
and glucose.20
There have been a few human studies with green   coffee 
extract. Thom investigated the efficacy and tolerability of 
a green coffee extract (Svetol®) added to instant coffee 
and compared within a randomized, placebo-controlled, 
double-blind study.21 The product reduces the absorption 
of different types of sugar from the gastrointestinal tract. 
Forty obese volunteers were included in the 12-week study. 
Body weight, body composition, and blood pressure were 
recorded at baseline and every month during the study. The 
results show a significant difference in weight reduction 
in favor of the active group (5.4 kg versus 1.7 kg, a 4% 
decrease versus the placebo). BMI decreased 2.9% or 10%. 
There was a significant inhibitory effect of the product 
compared to glucose, and instant coffee, on glucose absorp-
tion in a glucose tolerance test. This same commercial 
product was investigated by another group.22 The weight 
loss after 12 weeks was almost 5 kg in the treated groups 
and 2.5 kg in the placebo. A roasted and blended Arabica 
coffee rich in both green and roast bean constituents was 
tested in humans.23 The coffee product caused a significant 
weight loss averaging 0.7 kg and a significant 5% loss of 
body fat along with a significant decrease in lymphocyte 
DNA damage. A meta-analysis of the three published and 
unpublished studies on these products concluded that the 
average weight loss of 2.5 kg was moderate and the results 
were promising.26
The results of our study are much more dramatic for 
weight loss and BMI than previous green coffee extract 
investigations. The subjects averaged slightly over an 8 kg 
weight loss which was more than 10% of the body weight. For 
our study 10 of 16 subjects showed at least a 10% weight loss; 
five of the remaining six showed at least 5% weight loss; 
and the last individual showed a 4% weight loss. The most 
remarkable result was the fact that all 16 of the subjects 
were classified as overweight at the beginning of the study 
and at the end six of the subjects were now in the normal 
BMI category, ie, a normal weight for their height. It must 
be said that the daily dose of GCA in this study ranged from 
700 to 1050 mg and previous studies ranged from 180 to 
200 mg/day.24 There were no adverse effects in our study with 
the higher doses nor in the previous human studies accord-
ing to the authors of the meta-analysis paper. It should not 
be overlooked that there was a slight (4.88 ± 11.24 mmHg) 
though nonsignificant increase in systolic blood pressure 
over the course of the study, which appears to be isolated to 
the placebo arm (see Table 2).
Other limitations were the small sample size of the study 
and the short washout periods between arms. Also, taking 
GCA three times per day in the high-dose arm and twice 
per day in the low-dose arm may have alerted subjects to 
dosage amount, at least in the low-dose arm. We do not 
believe sample size to have been a problem, given the linear 
crossover design of the study. This eliminates any possibility 
of the results reflecting a difference between groups, instead 
of between dosages. Also, all variables were objective 
measures, and follow-up showed that a majority of subjects 
(14 of 16) were able to maintain their lowered weight after 
the completion of the study.
Five drugs had been approved by the Food and Drug 
Administration, all of which exhibit weight loss. There are 
two currently approved for weight loss with sibutramine 
  having been withdrawn from approval in 2011 due to 
  tachycardia.25 A recent review performed a meta-analysis 
of 30 trials of weight loss drugs of 1–4 years’ duration, 
ie, 16 orlistat (n = 10,631 participants), 10 sibutramine 
(n = 2623), and four rimonabant (n = 6365). Attrition rates 
averaged 30%–40%. Compared with placebo, orlistat 
reduced weight by 2.9 kg (2.9%) sibutramine by 4.2 kg 
(4.3%), and rimonabant by 4.7 kg (4.1%). BMI reductions 
were 1.0 with orlistat and 1.5 with sibutramine. Lack of 
adherence to treatment seems to be a major factor limiting 
the efficacy and effectiveness of antiobesity drugs.26 Thus 
the GCA with a weight loss of 8 kg (10.5%) and a BMI 
reduction of almost 3 makes the product superior to the 
prescription drugs. Weight loss of 5%–10% of initial body 
weight reduces cardiovascular and metabolic health risks 
associated with obesity.27
In a recent Israeli postmarketing study of over one   million 
individuals, fewer than 2% completed 12 months of weight 
loss medication.28 Those who continued for at least 4 months 
experienced a decrease in BMI of only 1 with a cost of 
$50–100 per month. GCA should provide an all natural, lower 
cost source as an effective therapy for overweight individuals. 
The efficacy for type 2 diabetics who have more coronary 
heart disease risk remains to be investigated.
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